Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | GCK | P35557 | 4/20 | 0.48 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22309177 | 1.00 | LMNA (0.49) | LMNAHPGDGCKSMPD1HDAC1 | |
| SCHEMBL25383158 | 0.87 | LRRK2 (0.49) | SMPD1HDAC8LRRK2CYP1A2 | |
| SCHEMBL30574775 | 0.87 | LRRK2 (0.49) | SMPD1HDAC8LRRK2CYP1A2 | |
| SCHEMBL15132070 | 0.86 | PTGER1 (0.47) | GCKPTGER1LRRK2CYP1A2 | |
| SCHEMBL31605181 | 0.86 | PTGER1 (0.47) | GCKPTGER1LRRK2CYP1A2 | |
| SCHEMBL20607933 | 0.86 | PTGER1 (0.54) | GCKPTGER1LRRK2CYP1A2 | |
| SCHEMBL23222953 | 0.83 | EGLN1 (0.51) | LMNAGCKSMPD1HDAC1HDAC8 | |
| SCHEMBL12398995 | 0.83 | HPGD (0.48) | LMNAHPGDSMPD1HDAC1HDAC8 | |
| SCHEMBL31605209 | 0.83 | PTGER1 (0.46) | GCKPTGER1LRRK2CYP1A2 | |
| SCHEMBL31466974 | 0.81 | CYP1A2 (0.53) | GCKCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4447963-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448493-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | Akebia Therapeutics, Inc. (US) | 2024-10-23 | — | — | EP | disclosed |
| CN-118715015-A | Selective PHD1 inhibitor compounds, compositions and methods of use | 阿克比治疗有限公司 | 2024-09-27 | — | — | CN | disclosed |
| CN-118414327-A | Pyridinamide compounds, compositions, and methods of use as selective PHD1 inhibitors | 阿克比治疗有限公司 | 2024-07-30 | — | — | CN | disclosed |
| WO-2023111985-A1 | PICOLINAMIDE COMPOUNDS AS SELECTIVE PHD1 INHIBITORS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023111990-A1 | SELECTIVE PHD1 INHIBITOR COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | AKEBIA THERAPEUTICS, INC. (US) | 2023-06-22 | — | — | WO | disclosed |